Literature DB >> 66167

Development of chronic liver disease after acute non-A, non-B post-transfusion hepatitis. Role of gamma-globulin prophylaxis in its prevention.

R G Knodell, M E Conrad, K G Ishak.   

Abstract

Progression of acute type B hepatitis to chronic liver disease and cirrhosis is well recognized, whereas no progression of acute type A hepatitis has as yet been documented. The natural history of acute non-A, non-B hepatitis has not been previously characterized. Ten cases of chronic liver disease were identified in 44 cases of acute non-A, non-B post-transfusion hepatitis. Age, sex, severity of acute illness, and prevalence of preoperative antibodies to known hepatitis-producing agents did not differ between the group whose hepatitis progressed to chronicity and the group whose hepatitis resolved. Less progression of acute hepatitis to chronic liver disease was seen in those patients receiving immune serum globulin preoperatively than in those receiving an albumin placebo (P = 0.009). Only 3 patients had clinical symptoms of hepatitis at the time of liver biopsy, and elevations of liver enzymes and gamma-globulin were mild. However, liver biopsy specimens in 8 of 10 patients showed chronic active hepatitis and an additional biopsy specimen showed cirrhosis. Acute non-A, non-B post-transfusion hepatitis often progresses to chronic active hepatitis. Preoperative gamma-globulin prophylaxis significantly reduces this progression. Identification and characterization of this viral agent(s) will further aid in the prevention of this undesirable complication of blood transfusion.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 66167

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  32 in total

1.  Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology.

Authors:  A Grant; J Neuberger
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

Review 2.  Non-A, non-B hepatitis.

Authors:  T N Dewar
Journal:  West J Med       Date:  1990-08

3.  Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for posttransfusion hepatitis.

Authors:  T Miyamura; I Saito; T Katayama; S Kikuchi; A Tateda; M Houghton; Q L Choo; G Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

Review 4.  Hepatitis C virus and transfusion transmitted liver disease: review.

Authors:  J C Underwood
Journal:  J Clin Pathol       Date:  1990-06       Impact factor: 3.411

Review 5.  Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups.

Authors:  H L Tillmann; M P Manns
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

6.  Paracetamol overdose as a cause of non-A, non-B hepatitis.

Authors:  C L Leen; P D Welsby
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-07

7.  Studies of lymphocyte subpopulations in the liver tissue and blood of patients with chronic active hepatitis (CAH).

Authors:  L S Si; T L Whiteside; R R Schade; D H Van Thiel
Journal:  J Clin Immunol       Date:  1983-10       Impact factor: 8.317

8.  Lower prevalence of anti-hepatitis C antibody in dialysis and renal transplant patients in Ireland.

Authors:  P J Conlon; J J Walshe; E G Smyth; E B McNamara; J Donohoe; M Carmody
Journal:  Ir J Med Sci       Date:  1993-04       Impact factor: 1.568

9.  Progression of hepatitis non-A, non-B to chronic active hepatitis: a histological follow-up of two cases.

Authors:  S Iwarson; J Lindberg; P Lundin
Journal:  J Clin Pathol       Date:  1979-04       Impact factor: 3.411

10.  Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study.

Authors:  R T Chung; F D Gordon; M P Curry; T D Schiano; S Emre; K Corey; J F Markmann; M Hertl; J J Pomposelli; E A Pomfret; S Florman; M Schilsky; T J Broering; R W Finberg; G Szabo; P D Zamore; U Khettry; G J Babcock; D M Ambrosino; B Leav; M Leney; H L Smith; D C Molrine
Journal:  Am J Transplant       Date:  2013-01-28       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.